Worth Watching Stocks: Rex Energy Corporation (REXX), RSP Permian, Inc. (RSPP), Merrimack Pharmaceuticals, Inc. (MACK)

Rex Energy Corporation (REXX) saw its value decrease by -7.3% as the stock dropped $-0.05 to finish the day at a closing price of $0.69. The stock was lighter in trading and has fluctuated between $0.23-$2.43 per share for the past year. The shares, which traded within a range of $0.675 to $0.75 during the day, are up by 96% in the past three months and up by 12.46% over the past six months. It is currently trading -2.97% below its 20 day moving average and 15.6% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $0 a share over the next twelve months. The current relative strength index (RSI) reading is 53.92.The technical indicator lead us to believe there will be no major movement any time soon, hold.

Rex Energy Corporation operates as an independent oil, natural gas liquid, and natural gas company in the Appalachian and Illinois basins in the United States. The company focuses on the Marcellus Shale, Utica Shale, and Burkett Shale drilling and exploration activities in the Appalachian Basin, as well as on developmental oil drilling on its properties in the Illinois Basins. As of December 31, 2015, it had estimated proved reserves of 680.4 billion cubic feet equivalent; and owned interests in approximately 1,819 oil and natural gas wells. Rex Energy Corporation was founded in 2007 and is headquartered in State College, Pennsylvania.

RSP Permian, Inc. (RSPP) shares were up in last trading by 1.39% to $43.7. It experienced higher than average volume on day. The stock increased in value by almost 7.58% over the past week and grew 1.96% in the past month. It is currently trading 0.57% above its 50 day moving average and 13.64% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -6.86% decrease in value from its one year high of $46.92. The RSI indicator value of 58.54, lead us to believe that it is a hold for now.

RSP Permian, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, development, and production of unconventional oil and associated liquids-rich natural gas reserves in the Permian Basin of West Texas. It owns interest in contiguous acreage blocks in the core of the Midland Basin, a sub-basin of the Permian Basin, primarily in the adjacent counties of Midland, Martin, Andrews, Dawson, Ector, and Glasscock. RSP Permian, Inc. was founded in 2010 and is headquartered in Dallas, Texas.

Merrimack Pharmaceuticals, Inc. (MACK) traded within a range of $3.17 to $3.28 after opening the day at $3.22. The company has seen its stock decrease in value by -20.59% so far this year. The stock was up close to 0.31% on light volume in last trading session and closed at $3.24 per share. After the recent gain, the stock is currently holding -64.08% below its 52 week high of $9.02 and 14.49% above its 12-month low of $2.83. The shares are down by over -51.13% in the last three months, and the RSI indicator value of 41.62 is neither bullish nor bearish, tempting investors to stay on the sidelines.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

 

Stocks To Track: Merrimack Pharmaceuticals, Inc. (MACK), Mueller Water Products, Inc. (MWA), The Western Union Company (WU)

Merrimack Pharmaceuticals, Inc. (MACK) climbed 1.58% during last trading as the stock added $0.05 to finish the day at $3.22 with about 2.38M shares changing hands, compared to its three month average trading volume of 4.01M. The $405.37M market cap company, which fluctuated between $3.16 and $3.36 during the day, currently situated 13.78% above its 52 week low of $2.83 and -64.3% away from its one year high of $9.02. The RSI of 38.66 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Mueller Water Products, Inc. (MWA) dropped $-0.25 to close the day at a new closing price of $12.76, a -1.92% decrease in value from its previous closing price that moved the stock 64.95% above its 52 week low of $7.8. A total of 2.38M shares exchanged hands during the day compared with its three month average trading volume of 1.28M. The stock, which fluctuated between $12.71 and $13.08 during the day, currently situated -10.14% below its 52 week high. The stock is down by -4.42% in the past one month and up by 18.15% over the past three months. With a one year target estimate of $14.5 and RSI of 39.34, the stock still has upside potential, making it a hold for now.

Mueller Water Products, Inc. manufactures and markets products and services for the use in transmission, distribution, and measurement of water in the United States, Canada, and internationally. The company operates in three segments: Mueller Co., Anvil, and Mueller Technologies. The Mueller Co. segment offers valves for water and gas systems, including iron gate, butterfly, tapping, check, knife, plug, and ball valves; dry-barrel and wet-barrel fire hydrants; pipe repair products, such as clamps and couplings used to repair leaks under the Mueller and Jones brand names; small valves, meter bars, and line stopper fittings for use in gas systems; and machines and tools for tapping, drilling, extracting, installing, and stopping-off. This segment sells its products primarily through waterworks distributors to various end user customers, including municipalities, water and wastewater utilities, gas utilities, and fire protection and construction contractors. The Anvil segment offers a range of products, including various fittings, couplings, hangers, valves, and related piping component system products for use in non-residential construction for HVAC, fire protection, industrial, power, and oil and gas end markets. This segment sells its products principally through distributors to various end users, including commercial contractors. The Mueller Technologies segment provides residential and commercial water metering products and systems; and leak detection and pipe condition assessment products and services primarily to municipalities and waterworks distributors, as well as to end users. Mueller Water Products, Inc. is headquartered in Atlanta, Georgia.

The Western Union Company (WU) had a light trading with around 2.37M shares changing hands compared to its three month average trading volume of 4.86M. The stock traded between $19.73 and $19.9 before closing at the price of $19.84 with 0.05% change on the day. The Englewood Colorado 80112 based company is currently trading 26.23% above its 52 week low of $16.23 and -12.6% below its 52 week high of $22.7. Both the RSI indicator and target price of 30.54 and $19.48 respectively, lead us to believe that it should be put on hold over the coming weeks.

The Western Union Company provides money movement and payment services worldwide. The company operates in three segments: Consumer-to-Consumer, Consumer-to-Business, and Business Solutions. The Consumer-to-Consumer segment offers money transfer services. This segment provides various options for sending funds, including walk-in and online money transfer, as well as account based money transfer services through a network of third-party agents using multi-currency and real-time money transfer processing systems. The Consumer-to-Business segment offers options to make one-time or recurring payments from consumers to businesses and other organizations, including utilities, auto finance companies, mortgage servicers, financial service providers, government agencies, and other businesses. It also provides various products, which provide consumers choices as to the payment channel and method of payment, including Speedpay, Pago Fácil, and Western Union Payments. This segment offers its services primarily through the phone and Online, as well as through its agent networks and selected company-owned locations. The Business Solutions segment facilitates payment and foreign exchange solutions, primarily cross-border and cross-currency transactions for small and medium size enterprises and other organizations, as well as for individuals. This segment provides its services through the phone, partner channels, and the Internet. As of December 31, 2015, the company had a network of approximately 500,000 agent locations in approximately 200 countries and territories. The Western Union Company was incorporated in 2006 and is headquartered in Englewood, Colorado.

 

Stocks Under Review: Merrimack Pharmaceuticals, Inc. (MACK), Sunoco LP (SUN), Kirby Corporation (KEX)

Merrimack Pharmaceuticals, Inc. (MACK) managed to rebound with the stock climbing 2.95% or $0.09 to close the day at $3.14 on light trading volume of 1.38M shares, compared to its three month average trading volume of 4.08M. The Cambridge Massachusetts 02139 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -51.01%, compared to the industry which has advanced 10.74% over the same period. With RSI of 35.45, the stock should still continue to rise and get closer to its one year target estimate of $9, making it a hold for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Sunoco LP (SUN) grew with the stock adding 1.93% or $0.56 to close at $29.56 on active trading volume of 1.37M compared its three months average trading volume of 1.25M. The Dallas Texas 75231 based company operating under the Oil & Gas Refining & Marketing industry has been trending up for the last 52 weeks, with the shares price now 2.44% up for the period and up by 9.93% so far this year. With price target of $30.67 and a 40.69% rebound from 52-week low, Sunoco LP has plenty of upside potential, making it a hold with a view buy.

Sunoco LP engages in the wholesale distribution and retail sale of motor fuels primarily in Texas, New Mexico, Oklahoma, Louisiana, Kansas, Maryland, Virginia, Tennessee, Georgia, and Hawaii. The company operates through two segments, Wholesale and Retail. It serves convenience stores and consignment locations, contracted independent convenience store operators, and other commercial customers. The company also distributes other petroleum products, such as propane and lubricating oils; and leases or subleases real estate properties used in the retail distribution of motor fuels. As of December 31, 2014, it operated 900 convenience stores and fuel outlets offering merchandise, food service, motor fuel, and other services in 8 states. Sunoco GP LLC serves as the general partner of the company. The company was formerly known as Susser Petroleum Partners LP and changed its name to Sunoco LP in October 2014. Sunoco LP is based in Dallas, Texas. Sunoco LP is a subsidiary of Susser Holdings Corporation.

Kirby Corporation (KEX) continued its upward trend with the stock climbing 5.88% or $3.8 to close the day at $68.45 on lower than average trading volume of 1.36M shares, compared to its three month average trading volume of 544.46K. The Houston Texas 77007 based company has been underperforming the shipping companies by 13.532% for last three months and its recent gains have pushed the stock slightly up 2.93% YTD, versus the shipping industry which is up 2.57% for the same period. The RSI of 59.05 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Kirby Corporation operates domestic tank barges and transports bulk liquid products. The company’s Marine Transportation segment provides marine transportation services and towing vessels transporting bulk liquid products, as well as operates tank barges throughout the Mississippi River System, on the Gulf Intracoastal Waterway, coastwise along three United States coasts, and in Alaska and Hawaii. This segment transports petrochemicals, black oil, refined petroleum products, and agricultural chemicals by tank barges. This segment also operates offshore dry-bulk barge and tugboat units that are engaged in the offshore transportation of dry-bulk cargoes in the United States coastal trade. As of February 19, 2016, this segment owned or operated 898 inland tank barges with 17.9 million barrels of capacity, 243 inland towboats, 70 coastal tank barges with 6 million barrels of capacity, 73 coastal tugboats, 6 offshore dry-bulk cargo barges, 7 offshore tugboats, and 1 docking tugboat. Its Diesel Engine Services segment sells replacement parts; provides service mechanics to overhaul and repair medium-speed and high-speed diesel engines, transmissions, reduction gears, and pumps; and maintains facilities to rebuild component parts or entire medium-speed and high-speed diesel engines, transmissions and reduction gears, and manufactures and remanufactures oilfield service equipment, including pressure pumping units. This segment serves inland and offshore barge operators, oilfield service companies, oil and gas operators and producers, offshore fishing companies, and marine and on-highway transportation companies, as well as the United States Coast Guard; the United States Navy; and power generation, nuclear, and industrial companies. The company was formerly known as Kirby Exploration Company, Inc. and changed its name to Kirby Corporation in 1990. Kirby Corporation was founded in 1921 and is headquartered in Houston, Texas.

 

3 Trending Stocks: Ascena Retail Group, Inc. (ASNA), Ironwood Pharmaceuticals, Inc. (IRWD), Merrimack Pharmaceuticals, Inc. (MACK)

Ascena Retail Group, Inc. (ASNA) failed to extend gains with the stock declining -2.08% or $-0.1 to close the day at $4.71 on light trading volume of 1.75M shares, compared to its three month average trading volume of 4.73M. The Mahwah New Jersey 07430 based company has been underperforming the apparel stores group over the past 52 weeks, with the stock losing -36.09%, compared to the industry which has dropped -8.29% over the same period. With RSI of 35.78, the stock should still continue to rise and get closer to its one year target estimate of $6.56, making it a hold for now.

Ascena Retail Group, Inc., through its subsidiaries, operates as a specialty retailer of apparel, shoes, and accessories for women and tween girls in the United States, Canada, and Puerto Rico. The company operates through six segments: ANN, Justice, Lane Bryant, maurices, dressbarn, and Catherines. It creates, designs, and develops a range of merchandise, including apparel, accessories, footwear, and intimates; lifestyle products comprising cosmetics, bedroom furnishings, and electronics; and wear-to-work, casual sportswear, footwear, and social occasion apparel. The company also offers casual clothing, career wear, dressy apparel, and active wear, as well as special occasion and classic apparel. Its principal brands comprise ANN TAYLOR, LOFT, ANN TAYLOR LOFT, LOU & GREY, JUSTICE, LANE BRYANT, LANE BRYANT OUTLET, CACIQUE, RIGHT FIT, MAURICES, DRESSBARN, CATHERINES, CATHERINES PLUS SIZES, MAGGIE BARNES, LIZ&ME, SERENADA, DRESSBAR, 6th & LANE, and MAURICES IN MOTION. As of July 30, 2016, the company operated approximately 4,900 stores. It also offers its products through its Websites, including anntaylor.com, LOFT.com, louandgrey.com, shopjustice.com, lanebryant.com, cacique.com, maurices.com, dressbarn.com, and catherines.com. The company was formerly known as Dress Barn, Inc. and changed its name to Ascena Retail Group, Inc. in January 2011. Ascena Retail Group, Inc. was founded in 1962 and is based in Mahwah, New Jersey.

Ironwood Pharmaceuticals, Inc. (IRWD) climbed 4.8% during last trading as the stock added $0.69 to finish the day at $15.07 with about 1.74M shares changing hands, compared to its three month average trading volume of 1.34M. The $2.2B market cap company, which fluctuated between $14.37 and $15.11 during the day, currently situated 105.03% above its 52 week low of $7.35 and -10.78% away from its one year high of $16.89. The RSI of 52.19 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, as well as in China, Hong Kong, and Macau. Ironwood Pharmaceuticals, Inc. also has license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Europe, as well as Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and Exact Sciences Corp. to co-promote Cologuard, a noninvasive stool DNA screening test for colorectal cancer. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals, Inc. (MACK) saw its value decrease by -0.96% as the stock dropped $-0.03 to finish the day at a closing price of $3.08. The stock was lighter in trading and has fluctuated between $2.83-$9.02 per share for the past year. The shares, which traded within a range of $3.04 to $3.14 during the day, are down by -41% in the past three months and down by -46.15% over the past six months. It is currently trading -6.62% below its 20 day moving average and -31.67% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $9 a share over the next twelve months. The current relative strength index (RSI) reading is 33.77. The technical indicator lead us to believe there will be no major movement any time soon, hold.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

 

Three Movers to Watch for: Heartland Express, Inc. (HTLD), The Chemours Company (CC), Merrimack Pharmaceuticals, Inc. (MACK)

Heartland Express, Inc. (HTLD) grew with the stock adding 1.08% or $0.22 to close at $20.55 on light trading volume of 1.68M compared its three months average trading volume of 539.55K. The North Liberty Iowa 52317 based company operating under the Trucking industry has been trending up for the last 52 weeks, with the shares price now 20.33% up for the period and up by 0.93% so far this year. With price target of $19.22 and a 28.17% rebound from 52-week low, Heartland Express, Inc. has plenty of upside potential, making it a hold with a view buy.

Heartland Express, Inc., through its subsidiaries, operates as a short-to-medium haul truckload carrier of general commodities. The company primarily provides nationwide asset-based dry van truckload service for shippers from Washington to Florida and New England to California; and temperature-controlled transportation services and non-asset-based freight brokerage services using company-owned and leased revenue equipment, as well as through independent contractor tractors. It transports appliances, automotive parts, consumer products, paper products, packaged foodstuffs, and retail goods. The company principally serves retailers and manufacturers. Heartland Express, Inc. was founded in 1978 and is headquartered in North Liberty, Iowa.

The Chemours Company (CC) dropped $-0.31 to close the day at a new closing price of $25.08, a -1.22% decrease in value from its previous closing price that moved the stock 713.58% above its 52 week low of $3.5. A total of 1.68M shares exchanged hands during the day compared with its three month average trading volume of 3.9M. The stock, which fluctuated between $24.29 and $25.25 during the day, currently situated -8.1% below its 52 week high. The stock is up by 11.96% in the past one month and up by 48.61% over the past three months. With a one year target estimate of $22.71 and RSI of 56.43, the stock still has upside potential, making it a hold for now.

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates in three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment produces and sells titanium dioxide (TiO2) under the Ti-Pure brand name to deliver whiteness, brightness, opacity, and protection in various applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, PVC window profiles, laminate papers, coated paper, and coated paperboard used for packaging. The Fluoroproducts segment provides fluoroproducts, such as hydrofluorocarbon refrigerants, and fluoropolymer resins and downstream products and coatings under the Teflon brand name. The Chemical Solutions segment offers industrial and specialty chemicals used in gold production, oil refining, agriculture, industrial polymers, and other industries in North America. This segment provides cyanides; and performance chemicals and intermediates, such as clean and disinfect chemicals, aniline, methylamines, glycolic acid, Vazo free radical initiators, and reactive metals. The company is headquartered in Wilmington, Delaware.

Merrimack Pharmaceuticals, Inc. (MACK) shares were down in last trading by -0.65% to $3.06. It experienced lighter than average volume on day. The stock increased in value by almost 2.68% over the past week and fell -27.32% in the past month. It is currently trading -34.1% below its 50 day moving average and -44.65% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -66.08% decrease in value from its one year high of $9.02. The RSI indicator value of 29.62, lead us to believe that it may correct downwards in the near term.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

 

Momentum Stocks in Focus: Pitney Bowes Inc. (PBI), Merrimack Pharmaceuticals, Inc. (MACK), Etsy, Inc. (ETSY)

Pitney Bowes Inc. (PBI) failed to extend gains with the stock declining -2.04% or $-0.33 to close the day at $15.85 on light trading volume of 2.23M shares, compared to its three month average trading volume of 2.64M. The Stamford Connecticut 06926 based company has been underperforming the business equipment group over the past 52 weeks, with the stock losing -12.98%, compared to the industry which has advanced 9.56% over the same period. With RSI of 50.78, the stock should still continue to rise and get closer to its one year target estimate of $19.17, making it a hold for now.

Pitney Bowes Inc. offers customer information management, location intelligence, and customer engagement technology products and solutions in the United States and internationally. The company operates in three segments: Small & Medium Business Solutions; Enterprise Business Solutions; and Digital Commerce Solutions. The Small & Medium Business Solutions segment is involved in the sale, rental, financing, and servicing of mailing equipment, software, and supplies; and provision of revolving credit and interest-bearing deposit solutions. The Enterprise Business Solutions segment offers equipment and services that enable large enterprises to process inbound and outbound mail. This segment provides production mail inserting and sortation equipment, production print systems, and supplies and related support services, as well as mail presort services. The Digital Commerce Solutions segment provides a range of solutions, including customer information management, location intelligence, customer engagement software, shipping management, and cross border ecommerce solutions as traditional software licenses, enterprise platforms, software-as-a-service, and on-demand applications, as well as offers related support services. The company’s solutions enable clients in marketing, shipping and mailing, and cross border ecommerce operations. Pitney Bowes Inc. sells its products through sales force, direct mailings, telemarketing, independent dealers and distributors, and Web channels to various business, governmental, institutional, and other organizations. The company was formerly known as Pitney Bowes Postage Meter Company. Pitney Bowes Inc. was founded in 1920 and is headquartered in Stamford, Connecticut.

Merrimack Pharmaceuticals, Inc. (MACK) retreated with the stock falling -5.63% or $-0.18 to close at $3.02 on light trading volume of 2.23M compared its three months average trading volume of 4.12M. The Cambridge Massachusetts 02139 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -52.14% down for the period and down by -25.98% so far this year. With price target of $9 and a 6.71% rebound from 52-week low, Merrimack Pharmaceuticals, Inc. has plenty of upside potential, making it a hold with a view buy.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Etsy, Inc. (ETSY) managed to rebound with the stock climbing 1.4% or $0.18 to close the day at $13 on higher than average trading volume of 2.23M shares, compared to its three month average trading volume of 1.55M. The Brooklyn New York 11201 based company has been outperforming the specialty retail, other companies by -4.0643% for last three months and its recent losses have trimmed gains to 10.36% YTD, versus the specialty retail, other industry which is up 11.41% for the same period. The RSI of 55.53 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Etsy, Inc. operates a marketplace to make, sell, and buy goods online and offline worldwide. The company through its technology-based platform connects a community of sellers and buyers. Etsy sellers offer goods in various online retail categories, including jewelry, stationery, clothing, home goods, craft supplies, and vintage items. The company was founded in 2005 and is headquartered in Brooklyn, New York.

 

Stocks To Track: Keryx Biopharmaceuticals, Inc. (KERX), Parsley Energy, Inc. (PE), Merrimack Pharmaceuticals, Inc. (MACK)

Keryx Biopharmaceuticals, Inc. (KERX) fell -6.41% during last trading as the stock lost $-0.34 to finish the day at $4.89 with about 2.91M shares changing hands, compared to its three month average trading volume of 1.49M. The $538.74M market cap company, which fluctuated between $4.76 and $5.25 during the day, currently situated 57.4% above its 52 week low of $3.11 and -37.24% away from its one year high of $7.8. The RSI of 28.26 indicates the stock is oversold at the current levels, buy for now.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, as well as treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. The company has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan. It also has strategic alliance with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.

Parsley Energy, Inc. (PE) dropped $-0.01 to close the day at a new closing price of $36.4, a -0.03% decrease in value from its previous closing price that moved the stock 136.52% above its 52 week low of $15.39. A total of 2.9M shares exchanged hands during the day compared with its three month average trading volume of 3.41M. The stock, which fluctuated between $36.18 and $36.89 during the day, currently situated -8.59% below its 52 week high. The stock is up by 2.48% in the past one month and up by 1.11% over the past three months. With a one year target estimate of $45.23 and RSI of 51.84, the stock still has upside potential, making it a hold for now.

Parsley Energy, Inc., an independent oil and natural gas company, engages in the acquisition, development, production, exploration, and sale of crude oil and natural gas properties in the Permian Basin located in West Texas and Southeastern New Mexico. As of December 31, 2015, its acreage position consisted of 110,967 net acres, including 84,441 net acres in the Midland Basin and 26,526 net acres in the Delaware Basin; and estimated proved oil and natural gas reserves were 123.8 MMBoe. The company was founded in 2008 and is headquartered in Austin, Texas.

Merrimack Pharmaceuticals, Inc. (MACK) had a light trading with around 2.9M shares changing hands compared to its three month average trading volume of 4.12M. The stock traded between $2.89 and $3.12 before closing at the price of $3.1 with 4.03% change on the day. The Cambridge Massachusetts 02139 based company is currently trading 9.54% above its 52 week low of $2.83 and -65.63% below its 52 week high of $9.02. Both the RSI indicator and target price of 26.47 and $9 respectively, lead us to believe that it could rise over the coming weeks.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

 

Worth Watching Stocks: United Continental Holdings, Inc. (UAL), Staples, Inc. (SPLS), Merrimack Pharmaceuticals, Inc. (MACK)

United Continental Holdings, Inc. (UAL) saw its value decrease by -3.31% as the stock dropped $-2.49 to finish the day at a closing price of $72.75. The stock was higher in trading and has fluctuated between $37.41-$76.8 per share for the past year. The shares, which traded within a range of $72.64 to $75.09 during the day, are up by 28.6% in the past three months and up by 52.93% over the past six months. It is currently trading -1.18% below its 20 day moving average and 2.61% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $85.28 a share over the next twelve months. The current relative strength index (RSI) reading is 48.64.The technical indicator lead us to believe there will be no major movement any time soon, hold.

United Continental Holdings, Inc., together with its subsidiaries, provides air transportation services in North America, the Asia-Pacific, Europe, the Middle East, Africa, and Latin America. The company transports people and cargo through its mainline and regional operations. As of December 31, 2015, it operated 1,236 aircraft. United Continental Holdings, Inc. also sells fuel; and offers catering, ground handling, and maintenance services for third parties. The company was formerly known as UAL Corporation and changed its name to United Continental Holdings, Inc. in October 2010. United Continental Holdings, Inc. was founded in 1934 and is headquartered in Chicago, Illinois.

Staples, Inc. (SPLS) shares were down in last trading by -1.09% to $9.06. It experienced lighter than average volume on day. The stock decreased in value by almost -1.2% over the past week and fell -7.93% in the past month. It is currently trading -2.8% below its 50 day moving average and 3.18% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -17.06% decrease in value from its one year high of $11.37. The RSI indicator value of 41.92, lead us to believe that it is a hold for now.

Staples, Inc., together with its subsidiaries, operates office products superstores. It operates in three segments: North American Stores & Online, North American Commercial, and International Operations. The company offers a range of office supplies, business technology products, facility and breakroom supplies, computers and mobility products, and office furniture under the Staples, Quill, and other proprietary brands. It also provides copy and print services, as well as technology services. The company sells and delivers office products and services directly to businesses and consumers through its Staples.com and Staples.ca, and Quill.com Websites, as well as through retail stores, and Internet and direct mail catalogs. As of January 30, 2016, it operated approximately 1,907 retail stores; and 104 distribution and fulfillment centers in the United States and internationally. The company was founded in 1985 and is based in Framingham, Massachusetts.

Merrimack Pharmaceuticals, Inc. (MACK) traded within a range of $2.83 to $3.03 after opening the day at $2.98. The company has seen its stock decrease in value by -26.96% so far this year. The stock was down close to -0.67% on light volume in last trading session and closed at $2.98 per share. After the recent fall, the stock is currently holding -66.96% below its 52 week high of $9.02 and 0.68% above its 12-month low of $2.83. The shares are down by over -41.8% in the last three months, and the RSI indicator value of 20.77 is bullish. They are not pointing to a rebound in the stock. We should get in as it looks to have found a bottom.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

 

Stocks In Queue: Valero Energy Corporation (VLO), Merrimack Pharmaceuticals, Inc. (MACK), Rice Energy Inc. (RICE)

Valero Energy Corporation (VLO) fell -1.02% during last trading as the stock lost $-0.68 to finish the day at $66.07 with about 3.64M shares changing hands, compared to its three month average trading volume of 5.23M. The $29.97B market cap company, which fluctuated between $65.53 and $66.77 during the day, currently situated 43.85% above its 52 week low of $46.88 and -7.46% away from its one year high of $71.4. The RSI of 45.3 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.

Valero Energy Corporation operates as an independent petroleum refining and marketing company in the United States, Canada, the Caribbean, the United Kingdom, and Ireland. It operates through two segments, Refining and Ethanol. The Refining segment is involved in refining, wholesale marketing, and bulk sales and trading activities. This segment produces conventional and premium gasolines, gasoline meeting the specifications of the California Air Resources Board (CARB), reformulated gasoline blendstock for oxygenate blending, diesel fuels, low-sulfur and ultra-low-sulfur diesel fuels, CARB diesel fuel, distillates, jet fuels, asphalts, petrochemicals, lubricants, and other refined products. As of February 19, 2016, it owned 15 petroleum refineries with a combined throughput capacity of approximately 3.0 million barrels per day. This segment also markets its refined products through bulk and rack marketing network; and through approximately 7,500 outlets under the Valero, Diamond Shamrock, Shamrock, Ultramar, Beacon, and Texaco brand names. The Ethanol segment produces and sells ethanol and distillers grains primarily to refiners and gasoline blenders, as well as to animal feed customers. This segment operates 11 ethanol plants with a combined ethanol production capacity of approximately 1.4 billion gallons per year. The company also operates a 50-megawatt wind farm; convenience stores; filling stations, as well as truckstop, cardlock, and home heating oil facilities; and credit card business. The company was formerly known as Valero Refining and Marketing Company and changed its name to Valero Energy Corporation in August 1997. Valero Energy Corporation was founded in 1955 and is headquartered in San Antonio, Texas.

Merrimack Pharmaceuticals, Inc. (MACK) gained $0.06 to close the day at a new closing price of $3.05, a 2.01% increase in value from its previous closing price that moved the stock 3.04% above its 52 week low of $2.96. A total of 3.62M shares exchanged hands during the day compared with its three month average trading volume of 4.18M. The stock, currently situated -66.19% below its 52 week high. The stock is down by -41.23% in the past one month and down by -38.13% over the past three months. With a one year target estimate of $9 and RSI of 20.86, the stock still has upside potential, making it a buy for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Rice Energy Inc. (RICE) had a light trading with around 3.61M shares changing hands compared to its three month average trading volume of 3.98M. The stock traded between $20.69 and $21.18 before closing at the price of $20.98 with 0.72% change on the day. The Canonsburg Pennsylvania 15317 based company is currently trading 164.9% above its 52 week low of $8.06 and -28.54% below its 52 week high of $29.36. Both the RSI indicator and target price of 46.21 and $31.5 respectively, lead us to believe that it should be put on hold over the coming weeks.

Rice Energy Inc., an independent natural gas and oil company, engages in the acquisition, exploration, and development of natural gas, oil, and natural gas liquid (NGL) properties in the Appalachian Basin. The company operates through two segments, Exploration and Production, and Midstream. As of December 31, 2015, it held approximately 92,000 net acres in the southwestern core of the Marcellus Shale, Pennsylvania; and approximately 56,000 net acres in the southeastern core of the Utica Shale located in Belmont County, Ohio. The company also has operations in the Upper Devonian Shale located on Pennsylvania acreage. It had 120 net producing wells in the Marcellus Shale; 4 net producing wells in the Upper Devonian Shale; and 19 net producing wells in the Utica Shale. The company is also involved in the gathering and compression of natural gas, oil, and NGL; and the provision of water services to support well completion activities. Rice Energy Inc. was founded in 2008 and is based in Canonsburg, Pennsylvania.

 

Investor’s Watch List: Ocwen Financial Corporation (OCN), Merrimack Pharmaceuticals, Inc. (MACK), CBS Corporation (CBS)

Ocwen Financial Corporation (OCN) had a active trading with around 3.84M shares changing hands compared to its three month average trading volume of 3.41M. The stock traded between $4.65 and $5.03 before closing at the price of $5 with 1.83% change on the day. The West Palm Beach Florida 33409 based company is currently trading 287.6% above its 52 week low of $1.29 and -22% below its 52 week high of $6.41. Both the RSI indicator and target price of 40.39 and $4.5 respectively, lead us to believe that it should be put on hold over the coming weeks.

Ocwen Financial Corporation, a financial services holding company, engages in servicing and origination of mortgage loans in the United States. Its Servicing segment provides residential and commercial mortgage loan servicing, special servicing, and asset management services to owners of mortgage loans and foreclosed real estate. This segment’s residential servicing portfolio includes conventional, government insured, and non-agency loans. The company’s Lending segment originates and purchases conventional and government-insured residential forward and reverse mortgage loans primarily through its correspondent lending arrangements, broker relationships, and directly with mortgage customers. Ocwen Financial Corporation was founded in 1988 and is headquartered in West Palm Beach, Florida.

Merrimack Pharmaceuticals, Inc. (MACK) continued its downward trend with the stock declining -1.97% or $-0.06 to close the day at $2.99 on light trading volume of 3.83M shares, compared to its three month average trading volume of 4.16M. The Cambridge Massachusetts 02139 based company has been underperforming the biotechnology group over the past 52 weeks, with the stock losing -49.92%, compared to the industry which has advanced 3.8% over the same period. With RSI of 19.18, the stock should still continue to rise and get closer to its one year target estimate of $9, making it a hold for now.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

CBS Corporation (CBS) shares were up in last trading by 1.98% to $63.49. It experienced lighter than average volume on day. The stock increased in value by almost 1.28% over the past week and fell -0.84% in the past month. It is currently trading 2.93% above its 50 day moving average and 14.04% above its 200 day moving average. Following the recent increase in price, the stock’s new closing price represents a -5.07% decrease in value from its one year high of $66.88. The RSI indicator value of 52.77, lead us to believe that it is a hold for now.

CBS Corporation operates as a mass media company worldwide. The company’s Entertainment segment distributes a schedule of news and public affairs broadcasts, and sports and entertainment programming; produces, acquires, and distributes programming, including series, specials, news, and public affairs; operates online content networks for information and entertainment; and produces, acquires, and distributes theatrical motion pictures. Its Cable Networks segment offers subscription program services, such as original series, theatrical feature films, documentaries, boxing and other sports-related programming, and special events; and owns and operates multiplexed channels. This segment also owns and manages Smithsonian Networks, which operates a channel featuring cultural, historical, scientific, and educational programs; and operates a CBS Sports Network, a 24-hour cable program service that provides college sports and related content. The company’s Publishing segment publishes and distributes adult and children’s consumer books in printed, digital, and audio formats; and develops special imprints and publishes titles based on the products, as well as that of third parties and distributes products for other publishers. This segment also delivers content; and promotes its products on its Websites, social media, and general Internet sites, as well as those related to individual titles. Its Local Broadcasting segment owns 30 broadcast television stations; owns and operates 117 radio stations in 26 U.S. markets and related online properties; and operates local digital properties in various U.S. markets that combine the company’s television and radio local media brands online to offer the latest news, traffic, weather, and sports information, as well as local discounts, directories, and reviews for local community. The company was founded in 1986 and is headquartered in New York, New York. CBS Corporation is a subsidiary of National Amusements, Inc.